Blue Earth completes $76.5 million Series A financing

Oxford, UK-based Blue Earth Therapeutics, an emerging leader in the development of therapeutic radiopharmaceuticals, today announces completion of a $76.5 million Series A financing.

The new funding comes from a broad spectrum of experienced biotech investors and enables Blue Earth Therapeutics to further advance its clinical stage PSMA-targeted radioligand therapies.

The company noted that an investment of this size is one of the larger direct investments of capital into the UK biotech sector. This builds on the success of sister company Blue Earth Diagnostics, which was originally funded as a standalone company by Syncona. Much of the company’s R&D activity is based in Oxford.